A Bayesian adaptive phase I/II clinical trial design with late‐onset competing risk outcomes

Yifei Zhang, Sha Cao, Chi Zhang, Ick Hoon Jin and Yong Zang

Biometrics, 2021, vol. 77, issue 3, 796-808

Abstract: Early‐phase dose‐finding clinical trials are often subject to the issue of late‐onset outcomes. In phase I/II clinical trials, the issue becomes more intractable because toxicity and efficacy can be competing risk outcomes such that the occurrence of the first outcome will terminate the other one. In this paper, we propose a novel Bayesian adaptive phase I/II clinical trial design to address the issue of late‐onset competing risk outcomes. We use the continuation‐ratio model to characterize the trinomial response outcomes and the cause‐specific hazard rate method to model the competing‐risk survival outcomes. We treat the late‐onset outcomes as missing data and develop a Bayesian data augmentation method to impute the missing data from the observations. We also propose an adaptive dose‐finding algorithm to allocate patients and identify the optimal biological dose during the trial. Simulation studies show that the proposed design yields desirable operating characteristics.

Date: 2021
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
https://doi.org/10.1111/biom.13347

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:bla:biomet:v:77:y:2021:i:3:p:796-808

Ordering information: This journal article can be ordered from
http://www.blackwell ... bs.asp?ref=0006-341X

Access Statistics for this article

More articles in Biometrics from The International Biometric Society
Bibliographic data for series maintained by Wiley Content Delivery ().